Enzyme Partners with 1Token to Solve Multi-Venue Asset Valuation
Enzyme Partners with 1Token to Solve Multi-Venue Asset Valuation
🔍 Fuzzy math problem
Asset managers running strategies across centralized exchanges, DeFi protocols, and multiple wallets face a critical challenge: accurate reporting. Inconsistent data sources make it difficult to provide reliable valuations to investors.
The Solution
Enzyme has partnered with 1Token to address this problem:
- Reconciles data from both CeFi and DeFi sources
- Provides unified valuation across multiple venues
- Helps managers maintain investor confidence through transparent reporting
This follows Enzyme's recent integration with Octav, showing a pattern of building infrastructure for cross-chain and multi-venue asset management.
Why It Matters
As crypto strategies become more complex, spanning different chains and platforms, accurate position tracking becomes essential for institutional adoption and investor trust.
The fastest way to lose investor trust? Fuzzy reporting. When a strategy spans wallets, exchanges, and on-chain, valuation gets messy. With support from @Crypto1Token, managers can reconcile CeFi + DeFi data and stand behind their numbers. More → enzyme.finance/blog-posts/enz…
On-Chain Spot Markets Gain Institutional Traction with Improved Execution
On-chain spot markets are narrowing the price gap with traditional venues while maintaining self-custody and instant settlement advantages. **Key developments:** - Capital efficiency improving through faster block times and enhanced execution infrastructure - Trading volume expanding as tooling matures - Institutional participants now actively monitoring the space **Market context:** This follows 3x year-over-year growth in USDC's share of spot trading volume through September 2025. Stablecoins are increasingly powering settlement and providing 24/7 market liquidity beyond traditional banking hours. The shift represents a tangible evolution from theoretical concepts to operational reality in capital markets infrastructure.
🔧 Onyx Timing Strategy
**Enzyme Onyx** addresses different protocol needs across three key stages: - **Pre-TGE**: Early participation incentives to build community - **Post-TGE**: Strengthen Total Value Locked (TVL) after token launch - **Mature stage**: Manage liquidity across multiple assets including stablecoins and liquid staking tokens The platform provides structured, on-chain strategies that protocols can adopt when timing is right for their development phase. Each stage requires different tooling approaches, but most protocols eventually need comprehensive on-chain financial infrastructure. [Explore Onyx](https://enzyme.finance/products/onyx?utm_source=x&utm_medium=organic&utm_content=post)
Chainlink CRE Automates Multi-Chain Asset Reporting for Fund Managers
**Multi-chain complexity solved**: As investment products expand across different blockchains, reporting becomes increasingly complex for asset managers. **Automated data sourcing**: Chainlink's CRE (Crypto Reporting Engine) automatically pulls and verifies NAV and performance data from: - On-chain sources - Centralized finance platforms - Traditional financial systems **Pain point addressed**: The solution eliminates manual reporting work that previously required tracking assets across multiple chains and platforms. **Verification built-in**: All data is automatically verified, reducing errors and ensuring accuracy for compliance and investor reporting.
Enzyme.Myso Introduces Institutional-Grade Options for On-Chain Yield Generation
Enzyme.Myso is advancing DeFi with institutional-grade on-chain options trading. The platform offers: - Native on-chain options strategies - Fully auditable transaction flows - Infrastructure designed for DAOs and institutions **Real-world implementation**: Compound DAO recently integrated covered calls into their treasury strategy using Enzyme.Myso, targeting approximately 15% APY while maintaining controlled risk exposure. This development signals a shift in how DAOs can optimize idle capital through sophisticated options strategies. *Learn more at* [Enzyme Finance](http://enzyme.finance/products/myso)